IP Library › Granted Patent US 12,195,550
Granted Patent B2
US 12,195,550 · App. 16/902,173 · Granted Jan 14, 2025

Targeting intracellular target-binding determinants with intracellular antibodies

Inventors: Richard H. Weisbart (Sepulveda, CA); Robert N. Nishimura (Sepulveda, CA)
Assignee: The United States of America as Represented by the Department of Veterans Affairs
C07K16/3053A61P35/00A61K2039/505C07K2317/31C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,550
App. No.
16/902,173
Granted
Jan 14, 2025
Kind
B2
Abstract

The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.

Claims (2)

1. A bispecific antibody comprising a first Fv fragment, wherein the first Fv fragment comprises a heavy chain variable domain comprising: a) a complementarity determining region (CDR) CDRH1 comprising SEQ ID NO: 11, b) a CDRH2 comprising SEQ ID NO: 13 and c) a CDRH3 comprising SEQ ID NO: 15; and, a light chain variable domain comprising: a) a CDRL1 comprising SEQ ID NO: 5, b) a CDRL2 comprising SEQ ID NO: 7, and c) a CDRL3 comprising SEQ ID NO: 9; and a second Fv fragment, wherein the second Fv fragment comprises a heavy chain variable domain comprising: a) a CDRH1 comprising SEQ ID NO: 23, b) CDRH2 comprising SEQ ID NO: 25 and c) CDRH3 comprising SEQ ID NO: 27; and, a light chain variable domain comprising: a) CDRL1 comprising SEQ ID NO: 17, b) CDRL2 comprising SEQ ID NO: 19, and c) CDRL3 comprising SEQ ID NO: 21.

2. The bispecific antibody of claim 1 , wherein the bispecific antibody has the amino acid sequence of SEQ ID NO: 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2022
From: WEISBART, RICHARD H.; NISHIMURA, ROBERT N.
To: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 058619/0096 →
Continuity (5)
Continuation 15042106 · Feb 11, 2016
Division 13844318 · Mar 15, 2013
Provisional Application 61618613 · Mar 30, 2012
Related Publication 20220089771A1 · Mar 24, 2022
Related Publication 20240052056A9 · Feb 15, 2024
References Cited (33)
US 3791932A · Schuurs et al. · 1974 [cited by applicant]
US 3817837A · Rubenstein et al. · 1974 [cited by applicant]
US 3897212A · Leon et al. · 1975 [cited by applicant]
US 4134792A · Boguslaski et al. · 1979 [cited by applicant]
US 4174384A · Ullman et al. · 1979 [cited by applicant]
US 4220722A · Rowley et al. · 1980 [cited by applicant]
US 4275149A · Litman et al. · 1981 [cited by applicant]
US 4299916A · Litman et al. · 1981 [cited by applicant]
US 4623627A · Huang et al. · 1986 [cited by applicant]
US 4690905A · Diamond et al. · 1987 [cited by applicant]
US 4812397A · Weisbart · 1989 [cited by applicant]
US 5264558A · Kim et al. · 1993 [cited by applicant]
US 5959084A · Ring · 1999 [cited by applicant]
US 6485977B1 · Colimer et al. · 2002 [cited by applicant]
US 7189396B1 · Weisbart · 2007 [cited by applicant]
US 7700544B2 · Kisilevsky et al. · 2010 [cited by applicant]
US 9283272B2 · Weisbart · 2016 [cited by examiner]
US 9701740B2 · Hansen et al. · 2017 [cited by applicant]
US 10683363B2 · Weisbart · 2020 [cited by examiner]
US 20050079184A1 · Chang · 2005 [cited by applicant]
US 20080292618A1 · Weisbart et al. · 2008 [cited by applicant]
US 20100143358A1 · Weisbart et al. · 2010 [cited by applicant]
US 20120070875A1 · Weisbart et al. · 2012 [cited by applicant]
US 20130266570A1 · Weisbart · 2013 [cited by examiner]
US 20160237165A1 · Weisbart · 2016 [cited by examiner]
WO WO199732602 · 1997 [cited by applicant]
WO WO2010138769 · 2010 [cited by applicant]
WO WO2012135831 · 2012 [cited by applicant]
Weisbart, R.H., et al. Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. international Journal of Oncology, 25:1113-1118,, 2004. [cited by applicant]
Weisbart, R.H. et al., A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets, Molecular Cancer Therapeutics, American Association for Cancer Research, May 9, 2012, p. 1-5. [cited by applicant]
U.S. Appl. No. 61/618,613, filed Mar. 30, 2012, Richard H. Weisbart. [cited by applicant]
U.S. Appl. No. 15/042,106 (U.S. Pat. No. 10,683,363), filed Feb. 11, 2016 (Jun. 16, 2020), Richard H. Weisbart (US Department of Veterans Affairs). [cited by applicant]
U.S. Appl. No. 13/844,318 (U.S. Pat. No. 9,283,272), filed Mar. 15, 2013 (Oct. 10, 2013), Richard H. Weisbart. [cited by applicant]